National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Dabrafenib, in combination with trametinib, is indicated for the adjuvant treatment of adult patients with stage III melanoma with a BRAF V600 mutation, following complete resection.

NCPE Assessment Process Complete
Rapid Review commissioned 30/01/2019
Rapid Review completed 21/03/2019
Rapid Review Outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of dabrafenib plus trametinib (Tafinlar® plus Mekinist®) compared with the current standard of care.